| Name | Title | Contact Details |
|---|
Accretive Health utilizes over a decade of operational expertise to bring measured impact to healthcare providers. We partner with hospitals and health systems to implement proprietary methodologies and relieve administrative burdens, allowing them to focus on their core mission: delivering high-quality care. Accretive Health’s operational framework centers on demonstrated capabilities and proficiencies across the end-to-end revenue cycle. Our solutions translate proven tactics and processes into measurable impact, leading to superior financial and organizational outcomes. Accretive Health utilizes over a decade of operational expertise to bring measured impact to healthcare providers. We partner with hospitals and health systems to implement proprietary methodologies and relieve administrative burdens, allowing them to focus on their core mission: delivering high-quality care. Accretive Health’s operational framework centers on demonstrated capabilities and proficiencies across the end-to-end revenue cycle. Our solutions translate proven tactics and processes into measurable impact, leading to superior financial and organizational outcomes.
Olympus-Gyrus ACMI is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Olympus-Gyrus ACMI is based in Memphis, TN. You can find more information on Olympus-Gyrus ACMI at www.gyrusacmi.com
Eden Health eliminates the hassle of healthcare for employers and their employees. We`re a new kind of doctor`s office that combines a private primary care practice, 24/7 telemedicine, and personalized insurance navigation into one simple platform. Eden provides an experience that employees love and saves employers money with seamless, data-driven healthcare.
Pearl City Nursing Home is a Pearl City, HI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III